Investigational drug · Phase 3
IBI362
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Sleep Apnea.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
26
Any phase or sponsor naming "IBI362"
First trial start
2024
Feb 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI362", any sponsor or status.
- Phase 310
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Sleep Apnea
- Obstructive
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Heart Failure With Mildly Reduced Ejection Fraction
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Adolescents With Obesity or Overweight With Weight-Related Comorbidities
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Hypertensive
Approved drugs for the same conditions: Obesity and weight management · Heart failure · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI362" as an intervention, largest first.
- A Study of IBI362 in Participants With Type 2 DiabetesPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05606913 · 731 participants · Start Jan 6, 2023 · Primary completion Jan 26, 2024
Drug: dulaglutide; IBI362 · For: Type 2 Diabetes
Sites: Beijing, China
- A Study of IBI362 in Participants With Obesity or OverweightPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05607680 · 610 participants · Start Nov 14, 2022 · Primary completion Aug 21, 2023
Drug: Placebo; IBI362 · For: Obesity Or Overweight
Sites: Xuancheng, China; Beijing, China; Luoyang, China · 23 sites in all
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Pivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06884293 · 479 participants · Start May 9, 2025 · Primary completion Dec 31, 2026
Drug: IBI362; semaglutide · For: Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Sites: Beijing, China
- A Study of IBI362 9 mg in Chinese Adults With ObesityPivotal-lookingStatus unknown
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06164873 · 462 participants · Start Dec 27, 2023 · Primary completion Jun 27, 2025
Drug: IBI362; Placebo · For: Obesity
Sites: Beijing, China
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)Pivotal-lookingRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT07083154 · 420 participants (planned) · Start Sep 27, 2025 · Primary completion Aug 1, 2029
Drug: Mazdutide; Placebo · For: Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes
Sites: Changsha, China; Changzhou, China; Nanjing, China · 8 sites in all
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06184568 · 349 participants · Start Feb 29, 2024 · Primary completion Sep 17, 2025
Drug: IBI362; Semaglutide · For: Type 2 Diabetes; Obesity
Sites: Beijing, China
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityPivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07469800 · 336 participants (planned) · Start Apr 23, 2026 · Primary completion Aug 1, 2026
Drug: IBI362; Placebo · For: Overweight; Obesity; Hypertensive
Sites: Shanghai, China
- A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04904913 · 328 participants · Start Jun 8, 2021 · Primary completion Mar 29, 2023
Drug: IBI362 · For: Overweight/ Obesity
Sites: Beijing, China
- A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05628311 · 319 participants · Start Jan 6, 2023 · Primary completion Oct 25, 2023
Drug: IBI362 · For: Type 2 Diabetes
Sites: Nanjing, China
- A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2Pivotal-lookingRecruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06931028 · 260 participants (planned) · Start Jun 12, 2025 · Primary completion May 7, 2027
Drug: IBI362 · For: Sleep Apnea; Obstructive; Obesity
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Nalisa DL, Cuboia N, Dyab E, et al. · Front Endocrinol (Lausanne) 2024
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
Ji L, Gao L, Jiang H, et al. · EClinicalMedicine 2022
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
Jiang H, Pang S, Zhang Y, et al. · Nat Commun 2022
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.
Ji L, Jiang H, An P, et al. · EClinicalMedicine 2021
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.